Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Yoshihiro Toyohara to Lead Teva Takeda from June
April 4, 2023
- Eisai to Offer Tazverik for NCC’s Patient-Proposed Study
April 4, 2023
- 19 of 41 Drug Makers Log P/B Ratio Below 1; TSE’s Quest to Boost Market Cap Not Easy
April 4, 2023
- 5 Otsuka Execs Earn 100 Million-Plus Pay in 2022: Securities Filing
April 4, 2023
- Chugai’s Annual Pay Tops 12 Million Yen for 1st Time: Securities Report
April 4, 2023
- Sanofi Seeks Dupixent Label Expansion into CSU in Japan
April 3, 2023
- Novartis Takes Over Radioligand Therapy Lutathera from Fujifilm in Japan
April 3, 2023
- Shionogi’s Xocova Now Available through Normal Commercial Channel
April 3, 2023
- Entyvio Hits Primary Goal in Pouchitis Study: Takeda
April 3, 2023
- Ultragenyx Plans Japan Submission of Evinacumab in May: CEO
March 31, 2023
- Takeda’s Iwasaki to Retire as Representative Director
March 31, 2023
- Pfizer Japan Files 20-Valent Pneumococcal Vaccine for Pediatric Use
March 31, 2023
- Sanofi Launches PD-1 Inhibitor Libtayo in Japan
March 31, 2023
- JCR, Alexion Pair Up for Neurodegenerative Disease
March 31, 2023
- Twymeeg Tops GP Promotion Ranking 2 Months Running, Belsomra Most Detailed among HPs in February
March 31, 2023
- Merck Poised to Work Together with Japan towards 90% HPV Vaccine Rate: Exec
March 31, 2023
- Astellas, Roche to Develop Combo Medical Device Solution for Diabetes
March 30, 2023
- Boehringer’s Japan Human Pharma Sales Up 5.6% in 2022
March 30, 2023
- Simulation Driven Decision-Making Support Necessary for R&D Strategy: Astellas Exec
March 29, 2023
- Pfizer Files Tick-Borne Encephalitis Vaccine in Japan
March 29, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…